On June 26, Gelunhui reported that Novo Nordisk said on Wednesday that due to the failure of the CLARION-CKD Phase III trial to reach its primary endpoint, the company will record an impairment loss of approximately DKK 5.7 billion (approximately USD 816.72 million) in the second quarter of 2024. CLARION-CKD is a multicenter, double-blind, placebo-controlled, randomized Phase III trial that uses ocedurenone for uncontrolled hypertension in late-stage chronic kidney disease (CKD) patients. Novo Nordisk purchased the kidney disease and hypertension drug ocedurenone from KBP Biosciences in October 2023, involving a total amount of approximately US$1.3 billion.
诺和诺德终止一项肾病药物试验 预计录得逾8亿美元减值损失
Novo-Nordisk has terminated a kidney disease drug trial, expected to record a write-down loss of over 800 million dollars.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.